Pasithea Therapeutics Corp. (KTTA)

In our clinical oncology trials, we are closely monitoring the Phase 1 dose-escalation safety and pharmacokinetics data for PAS-004, particularly given its targeting of MAPK pathway-driven advanced solid tumors and neurofibromatosis type 1 manifestations. The upcoming ESMO Congress 2026 presentation in October will be critical to validate whether this macrocyclic MEK inhibitor demonstrates a differentiated profile compared to legacy compounds. Technical protocol evaluations must account for the recent protocol expansion announced mid-year.

On our desk, KTTA presents a classic micro-cap biotech risk-reward dilemma. With a market cap hovering around $15.9 million and the stock trading down around $0.45 to $0.49, the market has deeply discounted the underlying fundamentals. CirclFi's valuation models show mixed sentiment with a low Quality Score of 4.5/10. Institutional investors are likely staying sidelined until the regulatory listing overhang is completely resolved.

Watching the macro risk factors, the most pressing threat to retail and institutional holders is the Nasdaq $1.00 minimum bid price compliance clock. Having received the deficiency notice in February 2026 with a deadline through August 2026, management faces intense pressure to either drive organic price recovery or execute corporate actions like a reverse stock split to avoid potential delisting and maintain public market liquidity.